Enveric Biosciences

Enveric Biosciences was granted a US patent for "Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives," which protects compositions and treatment methods for potentially neuroplastic and non‑hallucinogenic molecules. The patent strengthens the pipeline’s intellectual property and could make the candidates more attractive for licensing and partnerships in neuropsychiatric, neurological and addiction disorders. The stock rose about 7.1% in premarket trading after the announcement. » More on de.investing.com